Evidence map›Paper›PMID 39926542›Full record

ArticleACS omega2025

Design of a Multi-Epitope Vaccine against the Glycoproteins of Newcastle Disease Virus by Using an Immunoinformatics Approach.

Natolotriniavo T Randriamamisolonirina, Mirantsoa S Razafindrafara, Olivier F Maminiaina

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Natolotriniavo T RandriamamisolonirinaDepartment of Research and Quality Control, Malagasy Institute of Veterinary Vaccines, Antananarivo BP 04, Madagascar.ORCID https://orcid.org/0000-0001-5196-3737
Mirantsoa S RazafindrafaraDepartment of Research and Quality Control, Malagasy Institute of Veterinary Vaccines, Antananarivo BP 04, Madagascar.
Olivier F MaminiainaDepartment of Research and Quality Control, Malagasy Institute of Veterinary Vaccines, Antananarivo BP 04, Madagascar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newcastle disease (ND) causes major economic losses in poultry farming in Madagascar and many other countries. Previously, vaccines based on attenuated or inactivated Newcastle disease viruses (NDV) have been effective against this disease. However, their efficacy has declined due to viral mutations over time. To address this, two new multi-epitope vaccines (MEV) have been designed using immunoinformatics methods. First, 26 conserved epitopes from the fusion protein and 22 from the hemagglutinin-neuraminidase protein of 12 NDV strains isolated in Madagascar were selected to design the MEV. These epitopes were fused with specific linkers. Additionally, the adjuvant Avian Beta-Defensins-1 and the 6xHis tag were added to the N- and C-terminal ends of the vaccine formulations, respectively. The antigenicity, allergenicity, solubility, and physicochemical properties of the designed MEV were evaluated. Their three-dimensional structures were also modeled. Molecular docking studies and dynamic simulations were then conducted with the chicken Toll-like receptor 7 (TLR7) to assess the binding affinity of the MEV with this receptor. Finally, an immunological simulation was carried out to assess the ability of the candidate vaccine to induce an effective immune response. Through immunoinformatics analysis, both MEVs developed in this study were found to be highly antigenic, nonallergenic, and physicochemically stable. In addition, they showed significant interaction with the TLR7 receptor. They also have the capacity to trigger immune responses and promote the formation of memory cells following immunization. Therefore, these vaccines represent promising candidates for the control of ND. As this is an immunoinformatics study based on

Identifiers

PMID39926542
PMCPMC11800045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.